
Repligen (RGEN) Stock Forecast & Price Target
Repligen (RGEN) Analyst Ratings
Bulls say
Repligen is supported by a resilient bioprocessing demand backdrop, with consumables growing about 20% and strong momentum in Chromatography (+50%), Proteins (+40%), and Process Analytics, while capital equipment orders rose in the mid-teens to their highest level in five years. Its FY26 organic growth guidance narrowed to 12-13% from 10.5-13.5%, adjusted operating income guidance increased to $135-139m from $128-134m, and China’s >40% growth with record orders suggests improving global demand beyond North America and EMEA. Even with Filtration softness and headwinds from new therapeutic modalities in 2025 and largely through 2026, the company’s broad franchise, improving operating leverage, and recovery profile support a positive long-term outlook.
Bears say
Repligen is vulnerable to multiple compression because it trades at a premium to the high-growth MedTools peer group, yet that premium depends on sales growth and profitability that may not meet expectations. Its downside is amplified by a sluggish recovery in equipment demand, since reshoring optimism has not translated into actual purchase orders, and by competitive threats to ATF products that represent nearly 20% of sales. In addition, exposure to risky cell and gene therapy and mRNA end markets, plus regulatory and larger-competitor pressure, could undermine fundamentals across its bioprocessing portfolio.
This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.
Repligen (RGEN) Analyst Forecast & Price Prediction
Start investing in Repligen (RGEN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Repligen (RGEN) Forecast
Repligen (RGEN) Analyst Forecast & Price Prediction
Start investing in Repligen (RGEN)
Order type
Buy in
Order amount
Est. shares
0 shares